Streetbeat News

Products Services

ACIW

ACI Worldwide has been selected by Zimswitch to enhance fraud prevention in Zimbabwe's digital payment infrastructure using ACI's Fraud Management and Payments Intelligence solution.

Portfolio Pulse from

November 19, 2024 | 8:15 am

FTHI

FTHI employs a buy-write strategy on the S&P 500, offering a 9% yield but capping growth potential. It suits income-focused investors, not those seeking capital appreciation, as it underperformed the S&P 500 over the past decade.

Portfolio Pulse from

November 19, 2024 | 8:15 am

FSLY

Fastly's latest Global Security Research Report reveals that businesses are taking 25% longer to recover from cybersecurity incidents than expected, with an average recovery time of 7.3 months in 2024.

Portfolio Pulse from

November 19, 2024 | 8:15 am

FSLR

First Solar's proprietary thin-film technology provides superior efficiency and cost benefits over traditional panels. Government policies and tax credits, particularly from the Inflation Reduction Act, bolster its market dominance in the U.S. The company's strong financial performance, with significant revenue growth and a substantial backlog, highlights its robust market position and future earnings potential.

Portfolio Pulse from

November 19, 2024 | 8:15 am

CLVT

Clarivate Plc (NYSE:CLVT) has released its 2024 list of Highly Cited Researchers, highlighting influential researchers globally. The list includes 6,636 researchers from over 1,200 institutions across 59 countries. Clarivate emphasizes research integrity with enhanced filters to combat publication and citation manipulation.

Portfolio Pulse from

November 19, 2024 | 8:15 am

HAIN

Hain Celestial is rated a buy due to expected growth from restored infant formula supply, completed divestitures, and increased distribution in high-margin channels. Sales have been impacted by supply chain issues, divestitures, and promotional timing shifts, but these headwinds are expected to abate, improving growth prospects. Margin growth is anticipated from operating leverage, improved margin mix, and productivity initiatives.

Portfolio Pulse from

November 19, 2024 | 8:00 am

GSK

GSK has announced positive phase III trial results for linerixibat, a drug aimed at treating persistent itching in patients with primary biliary cholangitis (PBC), a rare liver disease. This development could potentially lead to a new treatment option for PBC patients.

Portfolio Pulse from

November 19, 2024 | 8:00 am

GSK

GSK's experimental drug, linerixibat, successfully met its primary goal in a late-stage trial for treating relentless itch linked to a rare autoimmune liver disease.

Portfolio Pulse from

November 19, 2024 | 7:45 am

CYTK

Cytokinetics and Bayer have entered into an exclusive licensing agreement for the development and commercialization of aficamten in Japan, with Cytokinetics receiving up to €70 million in upfront and near-term payments and up to €490 million in commercial milestone payments.

Portfolio Pulse from

November 19, 2024 | 7:45 am